Abeona Therapeutics Inc

+0.12 (+3.19%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)66.64M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.67 Million
Adjusted EPS-$0.65
See more estimates
10-Day MA$3.92
50-Day MA$3.96
200-Day MA$4.85
See more pivots

Abeona Therapeutics Inc Stock, NASDAQ:ABEO

1330 Avenue of the Americas, 33rd floor, New York, New York 10019
United States of America
Phone: +1.646.813.4701
Number of Employees: 90


Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.